- Home
- NYMT vs BCYC Comparison
NYMT vs BCYC Comparison
Compare NYMT & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYMT
- BCYC
- Stock Information
- Founded
- NYMT 2003
- BCYC 2009
- Country
- NYMT United States
- BCYC United Kingdom
- Employees
- NYMT N/A
- BCYC N/A
- Industry
- NYMT Real Estate Investment Trusts
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- NYMT Real Estate
- BCYC Health Care
- Exchange
- NYMT Nasdaq
- BCYC Nasdaq
- Market Cap
- NYMT 538.5M
- BCYC 511.4M
- IPO Year
- NYMT 2004
- BCYC 2019
- Fundamental
- Price
- NYMT $5.43
- BCYC $7.39
- Analyst Decision
- NYMT Buy
- BCYC Buy
- Analyst Count
- NYMT 5
- BCYC 8
- Target Price
- NYMT $7.13
- BCYC $29.14
- AVG Volume (30 Days)
- NYMT 879.3K
- BCYC 438.9K
- Earning Date
- NYMT 04-30-2025
- BCYC 05-01-2025
- Dividend Yield
- NYMT 14.72%
- BCYC N/A
- EPS Growth
- NYMT N/A
- BCYC N/A
- EPS
- NYMT N/A
- BCYC N/A
- Revenue
- NYMT $143,242,000.00
- BCYC $35,275,000.00
- Revenue This Year
- NYMT N/A
- BCYC N/A
- Revenue Next Year
- NYMT $20.60
- BCYC $0.27
- P/E Ratio
- NYMT N/A
- BCYC N/A
- Revenue Growth
- NYMT N/A
- BCYC 30.76
- 52 Week Low
- NYMT $5.01
- BCYC $6.10
- 52 Week High
- NYMT $7.25
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- NYMT 32.50
- BCYC 40.27
- Support Level
- NYMT $5.30
- BCYC $6.10
- Resistance Level
- NYMT $5.61
- BCYC $8.00
- Average True Range (ATR)
- NYMT 0.33
- BCYC 0.61
- MACD
- NYMT -0.07
- BCYC 0.14
- Stochastic Oscillator
- NYMT 26.92
- BCYC 46.07
About NYMT New York Mortgage Trust Inc.
New York Mortgage Trust Inc is a real estate investment trust for federal income tax purposes, in the business of acquiring, investing in, financing and managing mortgage-related and residential housing-related assets. The company's investment portfolio consists of Structured multi-family property investments such as multi-family CMBS an preferred equity in, and mezzanine loans to owners of multi-family properties. Distressed residential assets such as residential mortgage loans sourced from distressed markets and non-Agency RMBS. Second mortgages, Agency RMBS, and certain other mortgage-related and residential housing-related assets.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.